-
The process and challenges of language translation and cultural adaptation of study instruments: A case study from the NIDA CTN CHOICES-2 trial.
Collins JA, Lewin S, Shmueli-Blumberg D, Hoffman KA, Terashima JP, Korthuis PT, Horigian VE. The process and challenges of language translation and cultural adaptation of study instruments: A case study from the NIDA CTN CHOICES-2 trial. Journal of Ethnicity in Substance Abuse 2023;22(2):417-432.
-
Suicidality as a predictor of overdose among patients with substance use disorders.
Horigian VE, Schmidt RD, Shmueli-Blumberg D, Hefner K, Feinberg J, Kondapaka R, Feaster DJ, Duan R, Gonzalex S, Davis C, Marin-Navarrete R, Tross S. Suicidality as a predictor of overdose among patients with substance use disorders. Journal of Clinical Medicine 2022;11(21):6400.
-
Baseline representativeness of patients in clinics enrolled in the PRimary care Opioid Use Disorders treatment (PROUD) trial: Comparison of trial and non-trial clinics in the same health systems.
Wartko PD, Qiu H, Idu AE, Yu O, McCormack J, Matthews AG, Bobb JF, Saxon AJ, Campbell CI, Liu D, Braciszewski JM, Murphy SM, Burganowski RP, Murphy MT, Horigian VE, Hamilton LK, Lee AK, Boudreau DM, Bradley KA. Baseline representativeness of patients in clinics enrolled in the PRimary care Opioid Use Disorders treatment (PROUD) trial: Comparison of trial and non-trial clinics in the same health systems. BMC Health Services Research 2022;22:1593.
-
Specific polysubstance use patterns predict relapse among patients entering opioid use disorder treatment.
Pan Y, Feaster DJ, Odom G, Brandt L, Hu M, Weiss RD, Rotrosen J, Saxon AJ, Luo SX, Balise RR. Specific polysubstance use patterns predict relapse among patients entering opioid use disorder treatment. Drug and Alcohol Dependence Reports 2022;5:100128.
-
Machine learning techniques to explore clinical presentations of COVID-19 disease severity and to test the association with unhealthy opioid use (UOU): Retrospective cross-sectional cohort study.
Thompson HM, Sharma B, Smith D, Bhalla S, Erondu I, Hazra A, Ilyas Y, Pachwicewicz P, Sheth NK, Chhabra N, Karnik NS, Afshar M. Machine learning techniques to explore clinical presentations of COVID-19 disease severity and to test the association with unhealthy opioid use (UOU): Retrospective cross-sectional cohort study. JMIR Public Health and Surveillance 2022;8(12):e38158.
-
Risky alcohol use among patients dispensed opioid medications: A clinical community pharmacy study.
Cochran G, Charron E, Brown JL, Cernasev A, Hohmeier KC, Winhusen TJ. Risky alcohol use among patients dispensed opioid medications: A clinical community pharmacy study. Drug & Alcohol Dependence 2022;234:109406.
-
Analysis of health trajectories leading to adverse opioid-related events.
Gilson AS, Chartash D, Chang D, Hawk K, D'Onofrio G, Haimovich AD, Fiellin DA, Taylor RA. Analysis of health trajectories leading to adverse opioid-related events. AMIA Joint Summits on Translational Science 2021;248-256.
-
Development and testing of data infrastructure in the American College of Emergency Physicians’ clinical emergency data registry for opioid-related research.
Taylor A, Kinsman J, Hawk K, D'Onofrio G, Malicki C, Malcolm B, Goyal P, Venkatesh AK. Development and testing of data infrastructure in the American College of Emergency Physicians' clinical emergency data registry for opioid-related research. JACEP Open 2022;3(5):e12816.
-
Validity of the Single-Item Screen-Cannabis (SIS-C) for cannabis use disorder screening in routine care.
Matson TE, Lapham GT, Bobb JF, Oliver M, Hallgren KA, Williams EC, Bradley KA. Validity of the Single-Item Screen-Cannabis (SIS-C) for cannabis use disorder screening in routine care. JAMA Network Open 2022;5(11):e2239772.
-
Patient perspectives on opioid risk discussions in primary care.
Hooker SA, Essien IJ, Bogert-Spaniol CM, Rossom RC, Olson AW, Romagnoli KM, Solberg LI. Patient perspectives on opioid risk discussions in primary care. Journal of Patient-Centered Research and Reviews 2022;9(4):253-262.